Regenxbio Inc (NASDAQ:RGNX) SVP Curran Simpson sold 32,882 shares of the stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $63.76, for a total transaction of $2,096,556.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Curran Simpson also recently made the following trade(s):
- On Tuesday, October 16th, Curran Simpson sold 62,309 shares of Regenxbio stock. The shares were sold at an average price of $60.85, for a total transaction of $3,791,502.65.
Shares of Regenxbio stock opened at $61.94 on Friday. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -25.28, a PEG ratio of 9.27 and a beta of -0.49. Regenxbio Inc has a one year low of $23.25 and a one year high of $85.10.
Hedge funds have recently modified their holdings of the company. Meadow Creek Investment Management LLC purchased a new stake in shares of Regenxbio during the second quarter worth about $141,000. Riverhead Capital Management LLC grew its stake in shares of Regenxbio by 137.5% during the third quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 1,100 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Regenxbio by 1,212.0% during the second quarter. Meeder Asset Management Inc. now owns 2,178 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 2,012 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Regenxbio during the second quarter worth about $157,000. Finally, Glen Harbor Capital Management LLC purchased a new stake in shares of Regenxbio during the second quarter worth about $171,000. Institutional investors and hedge funds own 75.92% of the company’s stock.
Several research analysts have commented on RGNX shares. Raymond James lifted their price objective on shares of Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, September 7th. TheStreet upgraded Regenxbio from a “d+” rating to a “c” rating in a report on Monday, September 17th. BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a report on Saturday, November 3rd. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 target price for the company in a report on Wednesday, November 7th. Finally, Chardan Capital reduced their target price on shares of Regenxbio from $130.00 to $127.50 and set a “buy” rating for the company in a report on Wednesday, August 8th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Regenxbio currently has an average rating of “Buy” and an average price target of $82.93.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/11/23/regenxbio-inc-rgnx-svp-sells-2096556-32-in-stock.html.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: What is a stock split?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.